Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us  

| More

Lupin - Margin improvement factored in valuations - ICICI Securities

Posted On: 2021-05-16 06:41:13 (Time Zone: UTC)

Lupin's Q4FY21 performance was in-line with our expectations across parameters. Consolidated revenues declined 1.6% to Rs37.8bn (I-Sec: Rs38.9bn) with EBITDA margin expanding 500bps YoY and 70bps QoQ to 18.7% (I-Sec: 18.1%). US revenue improved 3.7% QoQ to US$195mn led by traction in Albuterol, despite weak flu season. Cost control initiatives have aided margin improvement but personnel costs were lower due to certain one-time savings. We expect the revenue mix to improve going ahead with higher India and US sales and cost control initiatives to support further margin improvement. However, near term outlook remains uncertain due to existing USFDA issues at plants and COVID-19 related disruptions. Considering recent rally in the stock price that has factored in expectation of margin improvement, we downgrade to REDUCE from Add.

- Revenue growth improvement in-line with expectation: Lupin's US revenues grew 3.7% QoQ to US$195mn (I-Sec: US$195mn) led by ramp-up in Albuterol. We expect US business to gradually improve in the coming quarters with growing contribution from Albuterol, and new launches (15-20 each year). India business grew 7.9% YoY during the quarter with recovery in industry growth across chronic and acute segments. We expect the company to revert to healthy positive growth in FY22, driven by chronic therapies (~60% of revenues). The EMEA businesses grew 2.7% YoY while Growth markets (LATAM+APAC) grew 8.3% YoY.

- Controlled cost supported the continuity in margin improvement: Company's gross margin improved 170bps YoY driven by improved product mix and efforts to reduce procurement costs but remained flat QoQ. One-time savings in personnel cost due to certain change in policies helped in 70bps QoQ improvement in EBITDA margin to 18.7%. We expect strict control on operational costs to continue. Growth in India and US would provide operating leverage to support EBITDA margin improvement to more than 20% by FY23E.

- Outlook: We believe recovery in India growth and gradual ramp-up in US sales would help revenue growth and margins improvement that also benefits from cost control. However, USFDA OAI/WL on four plants could deter growth. Overall, we expect revenue and PAT CAGR of 11.3% and 33.5%, over FY21-FY23E. Return ratios will continue to remain weak with RoE and RoCE being 13.0% and 11.1% respectively in FY23E.

- Valuation and risks: We raise earnings estimates by 3-4% to factor in cost control and lower tax rate. However, we believe recent rally in stock price has factored in expectation of margin improvement. Hence, we downgrade the stock to REDUCE from Add with a revised target price of Rs1,135/share based on 24xFY23E earnings and an additional Rs37/share for Spiriva opportunity (earlier: Rs1,080/share). Key upside risks: early resolution of USFDA issues and high value launches in US.

Shares of LUPIN LTD. was last trading in BSE at Rs.1178.8 as compared to the previous close of Rs. 1210.75. The total number of shares traded during the day was 329802 in over 9148 trades.

The stock hit an intraday high of Rs. 1233 and intraday low of 1165.95. The net turnover during the day was Rs. 392282538.

Source: Equity Bulls

Click here to send ur comments or to

Disclaimer:The article above is a gist / extract of the original report prepared by the research firm / brokerage firm. This article is not to be considered as an offer to sell or a solicitation to buy any securities. This article is meant for general information only., its employees or owners or the research firms, its employees or owners won't be responsible for any liability that may arise from information, errors or omissions in these articles. or its employees or owners / the research firms or its employees or clients or owners may from time to time hold positions in securities referred in this article. For detailed research reports, please contact the concerned research firm directly.

Other Headlines:

CESC Q4FY21 Results Review Report - Loss decline, strong CF make valuation attractive - HDFC Securities

White Goods & Durables - Analysis of pressure cooker market: TTK Prestige is key beneficiary - ICICI Securities

CESC - Good earnings in a challenging environment - ICICI Securities

Somany Ceramics - Walking the talk - ICICI Securities

DB Corp - Rise in newsprint price adds to risk - ICICI Securities

CEAT - Market share ambitions remain strong - ICICI Securities

Consumer Staples & Discretionary - Worm's world view #32: Conversations with paint dealers regarding price hikes - ICICI Securities

Oil & Gas - Oil, gas & spot LNG surge to bring gains for GAIL & OIL - ICICI Securities

Asset Management Companies - Positive trends to support earnings - ICICI Securities

Q4FY21 Result Update - Lemon Tree Hotels - ICICI Direct

Q4FY21 Company Update - Globus Spirits - ICICI Direct

Q4FY21 Result Update - DB Corp - ICICI Direct

Q4FY21 Result Update - Somany Ceramics - ICICI Direct

KEC International: Company Update - Building on diversification - HDFC Securities

LIC Housing Finance - Q4 FY21 Result Update - YES Securities

Entertainment Network Ltd - Beating on solutions business - ICICI Securities

Asahi India Glass - Operating leverage, product mix aid margins - ICICI Securities

Whirlpool of India - Market leading revenue growth - ICICI Securities

Lemon Tree Hotels - Wait for recovery gets longer - ICICI Securities

LIC Housing Finance - Stupendous growth momentum; needs to shore up provisioning and capital buffer - ICICI Securities

Quant Pick - Bank of Baroda - ICICI Direct

Company Update - Amara Raja Batteries - Investor Event Outcome - ICICI Direct

Q4FY21 Result Update - Bhel - ICICI Direct

Q4FY21 Company Update - NRB Bearings - ICICI Direct

CESC - Q4FY21 First Cut - ICICI Direct

Q4FY21 Result Update - Entertainment Network India - ICICI Direct

LIC Housing Finance Results Review Report - Balance sheet beefs up; P&L to stay soft - HDFC Securities

Jubilant FoodWorks 4QFY21 Results Review Report - Missing excitement; recovery priced in - HDFC Securities

BFSI Sector Update - MFI Consultation Paper Takeaways - Incrementally positive for NBFC-MFIs - HDFC Securities

Q4FY21 Result Update - JK Cement - ICICI Direct

Q4FY21 Result Update - Minda Industries - ICICI Direct

Stock Tales - Indo Count Industries - ICICI Direct

IPO Review - Krishna Institute of Medical Sciences Ltd - ICICI Direct

Q4FY21 Company Update - Greenply Industries - ICICI Direct

IPO Review - Dodla Dairy Ltd - ICICI Direct

Lemon Tree Hotels - Q4FY21 First Cut - ICICI Direct

Jubilant Foodworks - Q4FY21 investor call takeaways - YES Securities

Greenply Industries Ltd - Q4 FY21 Result Update - YES Securities

Whirlpool of India Ltd - Q4 FY21 Result Update - YES Securities

New India Assurance Report - CoRs disappoint yet again - HDFC Securities

Maintain BUY on Kajaria Ceramics - Performance shines through; outlook bright - HDFC Securities

Retain ADD on Deccan Cement - Volume strong; high other expense dents margin - HDFC Securities

Reiterate ADD on NHPC - Lower generation impacts earnings - HDFC Securities

Maintain BUY on JK Cement - Robust volume and utilisation - HDFC Securities

Maintain BUY on DLF - Gaining traction - HDFC Securities

Maintain BUY on Capacite Infraprojects - Marginal miss - HDFC Securities

DLF Ltd - Q4 FY21 Result Update - YES Securities

Greenply Industries Ltd - Q4FY21 first cut - YES Securities

Coal India - Coal makes a comeback - ICICI Securities

Kajaria Ceramics - Q4FY21 beat largely priced in - ICICI Securities

Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2020